Loading...
XNAS
LITS
Market cap8mUSD
Oct 08, Last price  
1.22USD
1D
-3.94%
1Q
20.79%
Jan 2017
-95.76%
IPO
-99.99%
Name

MEI Pharma Inc

Chart & performance

D1W1MN
XNAS:LITS chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
43.30%
Rev. gr., 5y
67.75%
Revenues
0
645,000674,000228,00084,00000000023,249,0001,622,0004,915,00028,913,00025,535,00040,697,00048,816,00065,297,00000
Net income
-71m
L+346.22%
-13,820,000-12,410,000-11,180,000-7,896,000-6,781,000-7,523,000-11,186,000-27,148,000-32,694,000-20,862,0002,670,000-40,068,000-16,819,000-47,170,000-41,310,000-54,450,000-31,840,00017,778,000-15,945,000-71,150,000
CFO
-9m
L-56.24%
-10,786,000-11,498,000-10,554,000-10,033,000-6,501,000-7,081,000-10,044,000-19,451,000-28,069,000-17,857,0003,486,000-21,302,000-29,423,00034,258,000-31,964,000-48,746,000-52,484,000-50,473,000-20,844,000-9,121,000
Dividend
Nov 16, 20231.75 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Lite Strategy, Inc. is a pharmaceutical company currently in the clinical development phase, primarily dedicated to creating novel treatments for various forms of cancer. Among its key initiatives, the company is advancing ME-344, an intravenously administered small molecule. This therapy is designed to inhibit mitochondrial oxidative phosphorylation and aims to combat specific cancer types, including human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and other solid tumors. In addition to its drug development activities, Lite Strategy also engages in the management of digital asset treasuries. The organization, which was formerly known as MEI Pharma, Inc., is slated to officially adopt the name Lite Strategy, Inc. in September 2025. Established in 2000, the company maintains its headquarters in San Diego, California.

Key people

Christine Anna White
Chairman of the Board · since 2015
David M. Urso
Chief Operating Officer, General Counsel · since 2018
Robert D. Mass
Chief Medical Officer · since 2011
Charles V. Baltic
Independent Director · since 2011
Kevan E. Clemens
Independent Director · since 2014
Frederick W. Driscoll
Independent Director · since 2018
William Dodge Rueckert
Independent Director · since 2011
URL
https://www.meipharma.com/
IPO date
Dec 18, 2003
Employees
102
Domiciled in
US
Incorporated in
US
Legal address
c/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST
Wilmington, DE 19801
US
Headquarters
3611 Valley Centre Drive, Suite 500
San Diego, CA 92130
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT